Puzo Michael J increased its position in Novo Nordisk A/S (NYSE:NVO – Free Report) by 10.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,500 shares of the company’s stock after acquiring an additional 500 shares during the quarter. Puzo Michael J’s holdings in Novo Nordisk A/S were worth $473,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Optimist Retirement Group LLC boosted its position in shares of Novo Nordisk A/S by 4.3% during the 3rd quarter. Optimist Retirement Group LLC now owns 2,747 shares of the company’s stock valued at $327,000 after acquiring an additional 112 shares in the last quarter. M. Kulyk & Associates LLC grew its holdings in Novo Nordisk A/S by 3.9% during the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company’s stock worth $274,000 after acquiring an additional 119 shares during the last quarter. Center for Financial Planning Inc. raised its position in Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares during the last quarter. Tradewinds Capital Management LLC lifted its stake in shares of Novo Nordisk A/S by 2.6% during the fourth quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company’s stock valued at $429,000 after acquiring an additional 124 shares during the period. Finally, Exencial Wealth Advisors LLC lifted its position in Novo Nordisk A/S by 0.5% during the 4th quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company’s stock valued at $1,987,000 after purchasing an additional 124 shares during the period. Institutional investors own 11.54% of the company’s stock.
Novo Nordisk A/S Stock Performance
NYSE NVO opened at $67.08 on Friday. The company has a fifty day moving average of $81.36 and a 200-day moving average of $97.26. Novo Nordisk A/S has a 52-week low of $63.67 and a 52-week high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a market capitalization of $301.04 billion, a P/E ratio of 20.39, a P/E/G ratio of 0.90 and a beta of 0.42.
Novo Nordisk A/S Increases Dividend
The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a $0.7874 dividend. This represents a dividend yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 47.72%.
Analyst Ratings Changes
NVO has been the subject of several recent analyst reports. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 21st. BMO Capital Markets decreased their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Finally, Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus price target of $145.25.
Read Our Latest Stock Analysis on NVO
Novo Nordisk A/S Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Further Reading
- Five stocks we like better than Novo Nordisk A/S
- What is a Bond Market Holiday? How to Invest and Trade
- Shares of RH Down Nearly 40%: Where Investors Can Turn To Now
- Earnings Per Share Calculator: How to Calculate EPS
- Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.